Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.23 (beta-galactosidase)
 14,648 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The expression of Herpes Simplex Virus 1 (HSV-1) glycoprotein C (gC), a well defined herpesvirus late gene, was studied by linking the promoter-regulatory region of this gene to the coding sequences for the bacterial enzyme, beta-galactosidase (beta-gal). A chimeric gene, containing the beta-gal gene under the control of gC sequences from -1350 to +30 relative to the mRNA start site, was inserted by homologous recombination into the thymidine kinase (TK) locus of the HSV-1 genome. Selection of the TK- recombinant virus by plaque assay was facilitated by addition of a beta-gal indicator to the agarose overlay. Recombinant virus containing the gC promoter-beta-gal chimeric gene faithfully expressed beta-gal as a viral late gene, as shown by the absence of beta-gal expression when viral DNA replication was inhibited with phosphonoacetic acid. In contrast, the inhibition of viral DNA replication had no effect on the expression of beta-gal when the beta-gal gene was under the control of the early HSV-1 TK promoter in a separate recombinant virus. Analysis of recombinant viruses containing 5' to 3' deletions in the gC regulatory region revealed no apparent difference in beta-gal expression as deletions extended from -1350 to -109 base-pairs (bp) before the RNA start site, demonstrating that sequences between -109 and +30 are sufficient for regulated gC expression in the viral genome. Analysis of the mRNA made by these recombinant viruses confirmed the results of the beta-gal assays, and demonstrated that the transcriptional start sites of the gC promoter-beta-gal chimeric genes were the same as the start site of the gC gene.
 ...
PMID:The use of beta-galactosidase as a marker gene to define the regulatory sequences of the herpes simplex virus type 1 glycoprotein C gene in recombinant herpesviruses. 284 20

The genomic localization of two immunodominant genes encoding two proteins of the Epstein-Barr virus capsid antigen (VCA) complex, VCA-p18 and VCA-p40, has been identified. For that purpose, lambda gt11-based cDNA libraries were constructed from HH514.c16 cells induced for virus production. The libraries were screened with a monoclonal antibody, EBV.OT41A, directed against VCA-p40 or with affinity-purified human antibodies against VCA-p18. Sequencing of the inserts of positive plaques showed that VCA-p18 and VCA-p40 are encoded within open reading frames (ORFs) BFRF3 and BdRF1, respectively. Peptide scanning analysis of the predicted protein of ORF BdRF1 resulted in defining the epitope of monoclonal antibody EBV.OT41A at the C-terminal region. The dominant VCA-p18 reactivity of human sera can be completely inhibited by preadsorption with Escherichia coli-expressed BFRF3-beta-galactosidase. Serum of a rabbit immunized with BFRF3-beta galactosidase reacts with a VCA-specific protein of 18 kDa. In addition, BFRF3-beta-galactosidase affinity-purified antibodies react with VCA-p18 of virus-producing cells (HH514.c16). Complete inhibition of viral DNA polymerase activity by phosphonoacetic acid is associated with the absence of RNAs and protein products of both ORFs, indicating that VCA-p18 and VCA-p40 are true late antigens.
 ...
PMID:Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. 768 3

To investigate the effect of murine cytomegalovirus (MCMV) infection on the developing mouse brain in vitro, we developed an infection system using cerebral slice cultures. Using a micromanipulator, the cerebral slices from mouse embryos on day 18.5 of gestation were injected in the subventricular zone with recombinant MCMV in which the lacZ gene was inserted into a late gene, and were cultured for 7 days. Viral infection, detected by beta-galactosidase reaction, was developed at the injection sites of the slices. The virus-infected spots in the slices were enhanced by adding tumor necrosis factor-alpha to the medium and inhibited by adding phosphonoacetic acid or ganciclovir. Sections from paraffin-embedded slices were subjected to immunohistochemical analyses. Neuronal cells, labeled with 5-bromo-2-deoxyuridine 24 h before cutting the slices, migrated to the cerebral cortex in the slices. Virus-infected neuronal cells expressing only the early viral antigen migrated to the cortex, whereas glial cells expressing the immediate early and late antigens tended to remain at the injected sites. The neuronal migration of infected cells was not observed in the cerebral slices from 7-day-old mice and viral infection was not detected after injection in the cerebral slices from 14- and 21-day-old mice. These results from these cerebral slices may reflect the infectious dynamics in vivo, and this system may provide a useful model for analysis of disorders of brain development caused by CMV.
 ...
PMID:Migration of virus-infected neuronal cells in cerebral slice cultures of developing mouse brains after in vitro infection with murine cytomegalovirus. 1060 34